Home Corporate Overview Human Medicine Veterinary Medicine Publications News Investor Relations Careers Contact Relations Investisseurs Accueil Message from the President Corporate Profile Management Team Scientific Committee Lead Compound Masitinib AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. Our pipeline is both in Human and Veterinary medicine. Our drugs are aimed to be used by hospitals and specialist physicians. We are commercializing our lead compound in Veterinary Medicine, and our pipeline is very well advanced in Human Medicine with several on-going phase 2 and phase 3 studies in oncology and non-oncology diseases. In parallel, AB Science has a robust drug discovery platform which has generated new compounds ready to be launched into preclinical development. We remain fully committed in meeting our objectives and we are very confident in our capacities to develop leading treatments that will dramatically change the lives of the patients. Alain Moussy Co-founder and CEO © COPYRIGHT AB SCIENCES. ALL RIGHTS RESERVED. I MASIVET® I KINAVET® I LEGAL NOTICE I DESIGN : AGENCE K2

Home Corporate Overview Human Medicine Veterinary medicine Publications News Investor Relations Careers Contact Investor Relations About AB Science Financial information Governance Regulated information Faq Contact Financial Calendar AB Science: Innovation at the heart of our scientific approach AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, a new class of targeted therapeutic molecules whose action consists of modifying intracellular signaling pathways. The company focuses its research activities on pathologies with high medical need (cancer, inflammatory diseases and diseases of the central nervous system) in human and animal health. AB Sciences works for the benefit of patients and pursues a clear goal: to transform basic science into medicine. AB Science: becoming an integrated pharmaceutical laboratory AB Science has made the decision to become an integrated pharmaceutical company, which develops its molecules until they are brought to the market and which markets them directly. This strategy offers the best potential for creating value, as the company retains all of the operating profit. © COPYRIGHT AB SCIENCES. ALL RIGHTS RESERVED. I MASIVET® I KINAVET® I LEGAL NOTICE I DESIGN: AGENCE K2